Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts

Rheumatology

Volumn 49, Issue 2, 2010, Pages 259-263

  Shi Wen, Xu ^a   Eastwood, Mark ^b   Stratton, Richard J ^a   Denton, Christopher P ^a   Leask, Andrew ^c   Abraham, David J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

smooth muscle actin; CCN2; Connective tissue growth factor; Myofibroblast; Rosiglitazone; Type I collagen

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FIBROSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

ACTINS; ADULT; CELLS, CULTURED; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PPAR GAMMA; SCLERODERMA, LOCALIZED; SKIN; THIAZOLIDINEDIONES;

EID: 77950433107     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep371     Document Type: Article

References (14)

1. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997;276:75-81.
2. Chen Y, Shiwen X, van Beek J et al. Matrix contraction by dermal fibroblasts requires TGFbeta/ALK5, heparan sulfate containing proteoglycans and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005;167:1699-711.
3. Dugina V, Fontao L, Chaponnier C, Vasiliev J, Gabbiani G. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. J Cell Sci 2001;114:3285-96.
4. Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostag Oth Lipid M 2003;71:1-22.
5. Burgess HA, Daugherty LE, Thatcher TH et al. PPAR gamma agonists inhibit TGF-beta induced pulmonary myofibroblasts differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005;288:L1146-53.
6. Kapoor M, McCann M, Liu S et al. Loss of PPARγ in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009;60:2822-9.
7. Shi-wen X, Denton CP, McWhirter A et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated collagen type I biosynthesis. Arthritis Rheum 1997;40:1237-44.
8. Shi-Wen X, Chen Y, Denton CP et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15:2707-19.
9. Eastwood M, McGrouther G, Brown RA. A culture force monitor for measurement of contraction forces generated in human dermal fibroblast cultures: evidence for cell-matrix mechanical signalling. Biochim Biophys Acta 1994;1201:186-92.
10. Holmes A, Abraham DJ, Chen Y et al. Sp1 is required for elevated CTGF expression in scleroderma fibroblasts. J Biol Chem 2003;278:41728-33.
11. Shiwen X, Pennington D, Holmes A et al. Autocrine over-expression of CTGF maintains fibrosis: RDA analysis of fibrosis in systemic sclerosis. Exp Cell Res 2000;259:213-24.
12. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009;174: 519-33.
13. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001;276:10594-601.
14. Chen Y, Shi-wen X, Eastwood M et al. ALK5 (TGFβ receptor type I) signaling contributes to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006;54:1309-16.